Technical Analysis for LJPC - La Jolla Pharmaceutical Company

Grade Last Price % Change Price Change
grade D 7.365 1.03% 0.08
LJPC closed down 4.58 percent on Monday, March 18, 2019, on 81 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical LJPC trend table...

Date Alert Name Type % Chg
Mar 18 Weak + Overbought Other 1.03%
Mar 18 Wide Bands Range Expansion 1.03%
Mar 18 Overbought Stochastic Strength 1.03%
Mar 15 Pocket Pivot Bullish Swing Setup -3.60%
Mar 15 Weak + Overbought Other -3.60%
Mar 15 Wide Bands Range Expansion -3.60%
Mar 15 Overbought Stochastic Strength -3.60%
Mar 15 Upper Bollinger Band Touch Strength -3.60%
Mar 14 Weak + Overbought Other 2.72%
Mar 14 Wide Bands Range Expansion 2.72%

Older signals for LJPC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The company's products include GCS-100, a Phase-1/2 clinical trial drug used for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome. In addition, the company is developing LJPC-101, a subcutaneous formulation of GCS-100; LJPC-201, an oral galectin-3 inhibitor; and LJPC-301, a monoclonal antibody designed to neutralize galectin-3. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.
Biopharmaceutical Cancer Life Sciences Pharmaceutical Industry Medication Chronic Kidney Disease Peptide Hormones Proteins Lectins Galectin Galectin 3 Hepatorenal Syndrome
Is LJPC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 38.39
52 Week Low 5.01
Average Volume 1,145,150
200-Day Moving Average 18.029
50-Day Moving Average 6.3214
20-Day Moving Average 6.5065
10-Day Moving Average 7.103
Average True Range 0.4567
ADX 29.22
+DI 29.2801
-DI 11.656
Chandelier Exit (Long, 3 ATRs ) 6.4499
Chandelier Exit (Short, 3 ATRs ) 6.8901
Upper Bollinger Band 7.7771
Lower Bollinger Band 5.2359
Percent B (%b) 0.81
BandWidth 39.056328
MACD Line 0.2278
MACD Signal Line 0.0596
MACD Histogram 0.1682
Fundamentals Value
Market Cap 161.28 Million
Num Shares 22.1 Million
EPS -5.12
Price-to-Earnings (P/E) Ratio -1.42
Price-to-Sales 5475.91
Price-to-Book 5.28
PEG Ratio -0.48
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.31
Resistance 3 (R3) 8.35 8.06 8.14
Resistance 2 (R2) 8.06 7.80 8.04 8.08
Resistance 1 (R1) 7.67 7.64 7.53 7.63 8.03
Pivot Point 7.38 7.38 7.30 7.36 7.38
Support 1 (S1) 6.99 7.12 6.85 6.95 6.55
Support 2 (S2) 6.70 6.96 6.68 6.50
Support 3 (S3) 6.31 6.70 6.44
Support 4 (S4) 6.27